Lomond Therapeutics Holdings, Inc.
5 clinical trials · Sponsor
◉ Watch Lomond Therapeutics Holdings, Inc.
| Record | Firm | Date |
|---|---|---|
| A Phase 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients (NCT07303660) | Lomond Therapeutics Holdings, Inc. | 2026-01-10 |
| A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies (NCT06708897) | Lomond Therapeutics Holdings, Inc. | 2025-04-08 |
| Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia (NCT06366789) | Lomond Therapeutics Holdings, Inc. | 2024-05-29 |
| Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers (NCT06787131) | Lomond Therapeutics Holdings, Inc. | 2024-05-21 |
| Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers (NCT06399315) | Lomond Therapeutics Holdings, Inc. | 2023-07-28 |
Track Lomond Therapeutics Holdings, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.